CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 120 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $2,000 | 0.0% | 358 | 0.0% | 0.00% | – |
| Q2 2019 | $2,000 | -60.0% | 358 | 0.0% | 0.00% | – |
| Q1 2019 | $5,000 | +150.0% | 358 | -0.6% | 0.00% | – |
| Q4 2018 | $2,000 | -50.0% | 360 | 0.0% | 0.00% | – |
| Q3 2018 | $4,000 | 0.0% | 360 | +20.0% | 0.00% | – |
| Q2 2018 | $4,000 | 0.0% | 300 | 0.0% | 0.00% | – |
| Q1 2018 | $4,000 | -75.0% | 300 | -82.7% | 0.00% | – |
| Q4 2017 | $16,000 | +14.3% | 1,735 | 0.0% | 0.00% | – |
| Q3 2017 | $14,000 | -62.2% | 1,735 | -73.0% | 0.00% | – |
| Q2 2017 | $37,000 | +32.1% | 6,435 | 0.0% | 0.00% | – |
| Q1 2017 | $28,000 | +1300.0% | 6,435 | +348.4% | 0.00% | – |
| Q4 2016 | $2,000 | – | 1,435 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |